HOME-BIOSCIENCES
9.11.2021 09:02:10 CET | Business Wire | Press release
Home Biosciences, Europe’s first venture builder fully dedicated to biotech, announced today a $15 million Seed financing led by Redmile Group and Sofinnova Partners.
Home Biosciences is the partner of choice for academics and scientists to transform their innovation into life changing therapies for patients. Every step of the way, Home Biosciences works together with leading scientific teams to build and grow sustainable businesses, by assembling the right expertise and structure. Each project is housed in a dedicated entity, a subsidiary, fully financed by Home Biosciences and led by teams entirely focused on the day-to-day execution of its projects with oversight from the Home Biosciences core management team.
"We are pleased to have such strong support from Redmile Group and Sofinnova Partners, two landmark investors in biotech, who recognize our potential to build a new type of biotech company, out of European science," said David Schilansky and Magali Richard , co-founders of Home-Biosciences. “Our ambition is to build a fully-fledged biotech company with an asset-centric operational model that aims to increase agility and R&D productivity. With the strong support of our shareholders, we look forward to leverage best-in-class science that will ultimately allow us to discover and deliver a new wave of first-in-class therapies.”
Proceeds from the financing will be used to accelerate the development of Home Biosciences’ pipeline while further strengthening its team. Specifically, the round will allow the company to advance its first venture, One Biosciences, as well as build a second one and a strong pipeline of projects. One Biosciences is focused on generating precision medicines by leveraging the power of single-cell technologies.
“Home Biosciences is pioneering an innovative model that fills an important gap in the European biotech ecosystem," said Antoine Papiernik , Managing Partner at Sofinnova Partners. “We are delighted to join forces with Redmile Group in supporting Europe’s first biotech venture builder in its mission to provide financial support and operational guidance, to create the groundbreaking therapies of the future.”
In connection with the Seed round, Ming Fang, a Managing Director of Redmile Group, and Antoine Papiernik, Managing Partner at Sofinnova Partners, will serve on the Board of Directors. They will join David Schilansky and Magali Richard, co-founders of Home Biosciences. An independent member of the Board is expected to be appointed in the near future.
About Home Biosciences
Home Biosciences is Europe’s first venture builder fully dedicated to biotech. Home Biosciences is the partner of choice for academics and scientists to transform their innovation into life changing therapies for patients. Every step of the way, Home Biosciences works with leading scientific teams to build and grow sustainable businesses, by assembling the right expertise and structure. With each of its projects housed in dedicated ventures and fully financed by Home Biosciences, its operating model allows full focus of its teams on scientific and operational excellence and rapid execution to significantly expedite and de-risk their discovery and development paths. For more information, visit: www.homebiosciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005152/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press release
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from
Andersen Global udvider sin juridiske virksomhed i Pakistan med et nyt medlemsfirma2.10.2026 22:36:00 CEST | Pressemeddelelse
Andersen Global styrker sin juridiske tilstedeværelse i Pakistan, idet Samdani & Qureshi, der har været samarbejdspartner siden 2021, skifter navn til Andersen Legal in Pakistan og bliver den seneste medlemsvirksomhed, der slutter sig til organisationen. Andersen Legal in Pakistan har hovedkontor i Islamabad og rådgiver både indenlandske og internationale klienter, herunder virksomheder, investorer, finansielle institutioner, offentlige enheder, udviklingsorganisationer og privatpersoner, om juridiske, kommercielle og regulatoriske forhold. Firmaet arbejder også med voldgift og tvistbilæggelse og rådgiver om komplekse transaktioner, investeringer, finansiering, projekter og tvister i Pakistan og på tværs af landegrænser. "Vores tilgang bygger på stærkt engagement fra ledelsen, klar kommunikation og disciplineret analyse med fokus på at levere rådgivning, som vores klienter kan omsætte til handling," sagde Nudrat Ejaz Piracha, partner hos Andersen Legal in Pakistan. "Ved at blive en del
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press release
Appointments expand emnify executive team to accelerate global growth emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press release
Enterprise software veteran to lead Tacton’s united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom